MedTrace Logo

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

NCT04420754 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-03-30

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.

Conditions

  • Anaplastic Thyroid Cancer
  • Relapsed/Refractory Poorly Differentiated Thyroid Cancer

Interventions

BIOLOGICAL

AIC100 CAR T Cells

Autologous CAR T cells directed against ICAM-1

Sponsors & Collaborators

  • AffyImmune Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Sonal Gupta, MD PhD · AffyImmune Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-28
Primary Completion
2026-08-04
Completion
2030-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420754 on ClinicalTrials.gov